IP Library › Granted Patent US 12,274,691
Granted Patent B2
US 12,274,691 · App. 17/215,466 · Granted Apr 15, 2025

Envenomation therapies and related pharmaceutical compositions, systems and kits

Inventor: Matthew R. Lewin (Corte Madera, CA)
Assignee: OPHIREX, INC
A61K31/404A61K9/0019A61K9/0043A61K31/16A61K31/167A61K31/24A61K31/245A61K31/381A61K31/405A61K31/445A61K31/541A61K38/57A61K39/39533A61K45/06C07K16/18C07K2317/55Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,274,691
App. No.
17/215,466
Granted
Apr 15, 2025
Kind
B2
Abstract

The invention provides methods of treatment, pharmaceutical compositions, systems and kits appropriate for first line and/or adjunct therapy with antivenom using at least one active component, in some instances at least two active components and in other instances no more than two active components selected from the group consisting of a selective secretory PLA 2 inhibitor (sPLA2 or PLA 2 inhibitor), a metalloproteinase inhibitor, a serine protease inhibitor, antivenom, one or more acetylcholinesterase inhibitors or a nAChR agonist paired with a mAChR antagonist, a NMDA receptor antagonist and a spreading factor inhibitor to treat a subject who suffers from an envenomation, preferably at the time of envenomation and often within a period of less than about an hour after an envenomation or 6 hours after an envenomation and throughout the course of treatment at time with or without anti-venom as an adjunct therapy after an envenomation by, for example, a snake or invertebrate.

Claims (5)

1. A method of treating a patient or subject suffering from envenomation by a snake comprising administering to said patient or subject, a therapeutically effective amount of a PLA2 inhibitor selected from the group consisting of varespladib, methylvarespladib, a pharmaceutically acceptable salt thereof, or a combination thereof, in combination with a pharmaceutically acceptable carrier, additive or excipient and at least one additional agent selected from the group consisting of a metalloproteinase inhibitor, a snake antivenom or a mixture thereof.

2. The method according to claim 1 wherein said PLA2 inhibitor is administered to said subject in the same medicament with or in a separate medicament from said additional agent(s).

3. The method according to claim 1 wherein said PLA2 inhibitor is administered in combination with a metalloproteinase inhibitor.

4. The method according to claim 1 wherein the PLA2 inhibitor and the additional agent(s) are administered to the subject by injection, intranasally, ocularly, orally, topically or by inhalation.

5. The method according to claim 1 wherein the PLA2 inhibitor is coadministered to the subject along with at least one metalloproteinase inhibitor selected from the group consisting of prinomastat, marimastat, vorinostat, cefixime, doxycycline, batimastat.

Continuity (5)
Division 15528418
Provisional Application 62082895 · Nov 21, 2014
Provisional Application 62243374 · Oct 19, 2015
Provisional Application 62131441 · Mar 11, 2015
Related Publication 20210260029A1 · Aug 26, 2021
References Cited (44)
US 20030225031A1 · Quay · 2003 [cited by applicant]
US 20050192243A1 · Savarese · 2005 [cited by applicant]
US 20070093518A1 · Wetherell et al. · 2007 [cited by applicant]
US 20090042939A1 · Leni · 2009 [cited by applicant]
US 20090062369A1 · Trias · 2009 [cited by applicant]
US 20130253060A1 · Mehendale · 2013 [cited by applicant]
US 20140087003A1 · Cisneros · 2014 [cited by applicant]
WO 199929726A1 · 1999 [cited by applicant]
WO 2009047762A1 · 2009 [cited by applicant]
WO 2014039920A1 · 2014 [cited by applicant]
Rucavado (Year: 2011). [cited by examiner]
Boilard (Year: 2006). [cited by examiner]
Edward A. Dennis, et al., Phospholipase A2 Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention., Chemical Reviews; pubs.acs.org/CR; REV 2011. [cited by applicant]
Florence Folmer a,b, Marcel Jaspars b, Marc Schumacher a, Mario Dicato a, Marc Diederich a,* Marine natural products targeting phospholipases A2. Biochemical Pharmacology 80 (2010) 1793-1800; journal homepage: www.elsev… [cited by applicant]
Winkel, Kenneth; et al. The unse of Anticholinesterase therapy. The University of Melbourne, Rfcd 1998;6 Digit Code Toxicology, chpt12, pp. 12.1-12.4, Introduction, case report. [cited by applicant]
Clark JD, et al. Potential therapeutic uses of phospholipase A2 inhibitors. Expert Opinion on Therapeutic Patents, 2004;14(7):937-950. [cited by applicant]
Rucavado A, et al. Effect of the metalloproteinase inhibitor batimastat in the systemic toxicity induced by Bothrops asper snake venom: understanding the role of metalloproteinases in envenomation. Toxicon, 2004;43(4):4… [cited by applicant]
Trinh HH, et al. Use of CROFAB antivenom in the management of a very young pediatric copperhead envenomation. The Journal of Emergency Medicine, 2005;29(2):159-162. [cited by applicant]
Ramar Perumal Samy, et al. Therapeutic application of natural inhibitors against snake venom phospholipase A2. Bioinformation, 2012;8(1):48-57. [cited by applicant]
Silvana Marcussi, et al. Snake Venom Phospholipase A2 Inhibitors: Medicinal Chemistry and Therapeutic Potential. Current Topics in Medicinal Chemistry, 2007;7(8). [cited by applicant]
Pereanez Jaime Andres, et al. The biflavonoid morelloflavone inhibits the enzymatic and biological activities of a snake venom phospholipase A2. Chemico-Biological Interactions, Elsevier Science Ireland, IR, vol. 220, 2… [cited by applicant]
Kabburalli Sunitha, et al. Neutralization of Haemorrhagic Activity of Vipor Venoms by . . . Anti-Haemorrhagic Activity of DFD. Basic & Clinical Pharmacology & Toxicology, 2011;109(4). [cited by applicant]
Ak Al-Asmari. Pharmacological characterization of rat paw edema induced by Naja haje arabica venom. Journal of Venomous Animals and Toxins including Tropical Diseases. J Venom Anim Toxins incl Trop Dis, 2005;11(1):51-67. [cited by applicant]
Ticli F K, et al. Rosmarinic acid, a new snake venom phospholipase A2 inhibitor from [cited by applicant]
Jaime Andra S Pereaa Ez, et al. Inhibitory Effects of Bile Acids on Enzymatic and Pharmacological Activities of a Snake Venom Phospholipase A from Group IIA. Journal of Protein Chemistry, Kluwer Academic Publishers-Plen… [cited by applicant]
Bma Carvakho, et al. Snake venom PLA2s Inhibitors Isolated from Brazilian Plants: Synthetic and Natural Molecules. Biomed Res Int. 2013;2013:153045. [cited by applicant]
Boilard Eric, et al. Secreted Phospholipase A2 inhibitors are also Potent Blocks of Binding to the M-Type Receptor. Biochemistry, American Chemical Society, vol. 45, No. 44. [cited by applicant]
Lewin Matthew R, et al. Varespladid appears to be a very potent broad-spectrum, inhibitor of snake venom PLA2s from six continents. Toxicon, 2016;117. [cited by applicant]
Lewin Matthew R, et al. Varespladid appears to be a very potent broad-spectrum inhibitor of snake venom Phospholipase A2s and a Possible Pre-Referral Treatment for Envenomation. Toxins, 2016;8(9). [cited by applicant]
Yiding Wang, et al. Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation. Molecules Online, 2018;23(2). [cited by applicant]
Lewin Matthew R, et al. Early Treatment with INtranasal Neostigmine Reduces Mortality In A Mouse Model of Naja Naja (Indean Cobra) Envenomation. Journal of Tropical Medicine, 2014;128(1):38-6. [cited by applicant]
Howes, et al. Neutralization of the Haemorrhagic Activities of Viperine Snake Venoms and Venom Metalloproteinases Using Synthetic Peptide Inhibitors and Chelators. Tox, 2007;49(5):734-739. [cited by applicant]
Bustillo Soledad, et al. Synergism Between Baltergin Metalloproteinase and BA SPII RP4 Plafromvenom on Skeletal Muscle (C2C12) Cells. Toxicon, 2011;59(2):338-343. [cited by applicant]
Rucavado Alexandra, et al. Proteomics of Wound Exudate in Snake Venom-Induced Pathology: Search for Biomakers to Assess Tissue Damage and Therapeutic Success. Journal of Proteome Research, 2011;10(4):1987-2005. [cited by applicant]
Oslund RC, et al. Highly Specific and Broadly Potent Inhibitors of Mammalian Secreted Phospholipases A2. J Med Chem, 2008;51:4708-4714. [cited by applicant]
Ticli FK, et al. Rosmarinic acid, a new snake venom phospholipase A2 inhibitor from [cited by applicant]
Diz Filho Ebs, et al. Enzymatic and structural characterization of new PLA2 isoform isolated from white venom of [cited by applicant]
Teixeira C, et al. Inflammation induced by Bothrops asper venom. Toxicon, 2009;54:67-76. [cited by applicant]
Vanzolini PE, Calleffo ME. A taxonomic bilbiography of the South American snakes of the [cited by applicant]
Golberg SR, Philip CR. Reproduction in the Mojave Rattlesnake, [cited by applicant]
Marchi-Salvador DP, et al. Crystal structure of a phospholipase A2 homolog complexed with p-bromophenacyl bromide reveals important structural changes associated with the inhibition of myotoxic activity. Biochimica et B… [cited by applicant]
Balsinde J, et al. Regulation and Inhibition of Phospholipase A2. Annu Rev Pharmacol Toxicol, 1999;39:175-189. [cited by applicant]
Araujo MS, Martins M. The defensive strike of five species of lanceheads of the genus [cited by applicant]
Nicholls, Stephen J., Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome The VISTA-16 Randomized Clinical Trial, JAMA Jan. 15, 2014 vol. 311, No. 3, pp. 253-262, Published online Nov. 18, … [cited by applicant]